Supriya Lifescience Limited has submitted a regulatory filing to BSE Limited and National Stock Exchange of India Limited regarding ongoing judicial proceedings. This communication is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and serves as a continuation of earlier intimations on the same matter.
The company reports that the judicial matter has been admitted by the Hon'ble Supreme Court of India and is currently listed for hearing. In an interim order, the Hon'ble Supreme Court has directed that no coercive action shall be taken against the directors, officers, or officials of the petitioner company, subject to the specific terms and conditions outlined in the court's order.
The matter remains sub judice (under judicial consideration) and pending before the Hon'ble Supreme Court. The company has committed to continuously monitor the proceedings and will keep both stock exchanges and its shareholders informed of any material developments as they are received from the Hon'ble Court or otherwise in accordance with applicable laws and regulations.
Financial Impact
Financial impact not quantified in the disclosure. The interim relief order prevents coercive actions against company personnel but does not specify financial implications.